ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
22 Febbraio 2024 - 1:47PM
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for treatment of patients with inflammatory and renal
diseases who have significant unmet medical needs, announces
availability of a new white paper titled, “Inflammasome ASC
Inhibitor IC 100, Promising Therapeutic Potential For Neurological
Diseases.” The white paper highlights data demonstrating that
activation of more than one type of inflammasome and associated
release of ASC specks leads to development and progression of
common neurological diseases. The white paper then summarizes data
from preclinical research led by Drs. Robert W. Keane and Juan
Pablo de Rivero Vaccari at the University of Miami Miller School of
Medicine demonstrating strong pharmacologic and mechanistic
proof-of-concept for Inflammasome ASC Inhibitor IC 100 in animal
models and tissue cultures representative of a variety of
neurological conditions: multiple sclerosis, age-related
inflammation, Alzheimer’s disease, traumatic brain injury, and
spinal cord injury. Drs. Keane, de Rivero Vaccari, and their
colleagues currently have research underway in Parkinson’s disease
that was funded through a grant with the Michael J. Fox Foundation.
To access a copy of the white paper, Click Here.
“We are excited about the potential of targeting multiple
inflammasome pathways and ASC specks with Inflammasome ASC
Inhibitor I00 to control the damaging inflammation contributing to
neurological diseases that negatively impact the quality of life in
millions of people,” said Stephen C. Glover, Co-founder, Chairman,
CEO, and President of ZyVersa. “We are nearing completion of our
preclinical program for IC 100 and expect to file an IND in the
fourth quarter of 2024, with plans to initiate a phase 1 clinical
trial in early 2025.”
About Inflammasome ASC Inhibitor IC 100
IC 100 is a novel humanized IgG4 monoclonal antibody that
inhibits the inflammasome adaptor protein ASC. IC 100 attenuates
both initiation and perpetuation of the inflammatory response. It
does so by binding to a specific region of the ASC component of
multiple types of inflammasomes, including NLRP1, NLRP2, NLRP3,
NLRC4, AIM2, and Pyrin. Intracellularly, IC 100 binds to ASC
monomers, inhibiting inflammasome formation, thereby blocking
activation of IL-1β early in the inflammatory cascade. IC 100 also
binds to ASC Specks, both intracellularly and extracellularly,
further blocking activation of IL-1β and the perpetuation of the
inflammatory response that is pathogenic in inflammatory diseases.
Because active cytokines amplify adaptive immunity through various
mechanisms, IC 100, by attenuating cytokine activation, also
attenuates the adaptive immune response.
About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty
biopharmaceutical company leveraging advanced, proprietary
technologies to develop first-in-class drugs for patients with
renal and inflammatory diseases who have significant unmet medical
needs. The Company is currently advancing a therapeutic development
pipeline with multiple programs built around its two proprietary
technologies – Cholesterol Efflux Mediator™ VAR 200 developed to
ameliorate renal lipid accumulation that damages the kidneys'
filtration system in patients with glomerular kidney diseases, and
Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation
associated with numerous CNS and other inflammatory diseases. For
more information, please visit www.zyversa.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management’s intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities.
Corporate and IR Contact:
Karen CashmereChief Commercial
Officerkcashmere@zyversa.com786-251-9641
Grafico Azioni ZyVersa Therapeutics (NASDAQ:ZVSA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni ZyVersa Therapeutics (NASDAQ:ZVSA)
Storico
Da Giu 2023 a Giu 2024